Literature DB >> 31773496

Determination of serum free light chains as a marker of systemic lupus flare.

Ana Belén Rodríguez-Cambrón1, Juana Jiménez-Jiménez2, María Ángeles Blázquez-Cañamero3, Francis Rey Pazos4, Cristina Macía-Villa4, María Alcalde-Villar4, Paz Collado-Ramos4, Félix Manuel Cabero Del Pozo4, Eva Álvarez-Andrés4, Ana Cruz-Valenciano4.   

Abstract

INTRODUCTION: The aim of this study was to explore the usefulness of the determination of free light chains (FLC) in serum as a biomarker of flare in patients with systemic lupus erythematosus (SLE) and to analyze the differences in their discriminatory capacity with complement C3 and C4.
METHODS: This was a prospective cohort study. The definition of flare was based on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index. The discriminatory capacity of FLC and C3 and C4 levels was compared using receiver operating characteristic (ROC) curves and the area under the curve (AUC).
RESULTS: Forty-six patients were enrolled. Patients with SLE flare showed significantly lower C3 (p = 0.025) and C4 levels (p = 0.028), as well as a higher concentration of lambda light chains (λ-LC) (p = 0.028) compared with the non-flare group. λ-LC, as opposed to kappa light chains and total light chains, demonstrated a discriminatory capacity for detecting the presence of SLE flare (AUC 0.781), with 100% sensitivity, 65% specificity, and 69.6% of patients correctly classified for a cutoff point of ≥ 19.5 mg/L. Complement C3 and C4 also showed a high discriminatory capacity for SLE flare (AUC 0.804 and 0.837, respectively). Comparing λ-LC, C3, and C4, the last one demonstrates better discriminatory capacity for SLE flare with the highest AUC (0.837; 95% CI 0.663-1.000).
CONCLUSIONS: λ-LC have good discriminatory capacity for SLE flare and could be useful as a biomarker of SLE exacerbation.Key Points• The usefulness of free light chains as a biomarker could be compared with complement.• Lambda free light chains have good discriminatory capacity for SLE flare.• Free light chains are a promising marker of SLE activity.

Entities:  

Keywords:  Biomarker; Flare; Free light chains; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2019        PMID: 31773496     DOI: 10.1007/s10067-019-04827-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

1.  Urinary free light chains: a potential biomarker in lupus nephritis.

Authors:  Rohit Aggarwal
Journal:  Rheumatology (Oxford)       Date:  2013-09-24       Impact factor: 7.580

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: comment on the article by Esdaile et al.

Authors:  R J Smeenk; L A Aarden; T J Swaak
Journal:  Arthritis Rheum       Date:  1996-12

Review 4.  Free light chains and autoimmunity.

Authors:  Cecilia Napodano; Krizia Pocino; Donato Rigante; Annunziata Stefanile; Francesca Gulli; Mariapaola Marino; Valerio Basile; Gian Ludovico Rapaccini; Umberto Basile
Journal:  Autoimmun Rev       Date:  2019-03-04       Impact factor: 9.754

5.  Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.

Authors:  Rohit Aggarwal; Winston Sequeira; Rediet Kokebie; Rachel A Mikolaitis; Lewis Fogg; Alison Finnegan; Anna Plaas; Joel A Block; Meenakshi Jolly
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-06       Impact factor: 4.794

6.  Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light-chain immunoglobulin.

Authors:  J E Hopper; W Sequeira; J Martellotto; E Papagiannes; L Perna; J L Skosey
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

7.  Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis.

Authors:  Xiaoli Deng; Cynthia S Crowson; S Vincent Rajkumar; Angela Dispenzieri; Dirk R Larson; Terry M Therneau; Eric L Matteson; Robert A Kyle; Jerry A Katzmann; Sherine E Gabriel; John M Davis
Journal:  J Rheumatol       Date:  2015-01-15       Impact factor: 4.666

8.  B cell hyperactivity and its relation to distinct clinical features and the degree of disease activity in patients with systemic lupus erythematosus.

Authors:  T Sakane; N Suzuki; S Takada; Y Ueda; Y Murakawa; T Tsuchida; Y Yamauchi; T Kishimoto
Journal:  Arthritis Rheum       Date:  1988-01

9.  Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies.

Authors:  Anette H Draborg; Magnus C Lydolph; Marie Westergaard; Severin Olesen Larsen; Christoffer T Nielsen; Karen Duus; Søren Jacobsen; Gunnar Houen
Journal:  PLoS One       Date:  2015-09-24       Impact factor: 3.240

Review 10.  Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects.

Authors:  Emanuele Cozzani; Massimo Drosera; Giulia Gasparini; Aurora Parodi
Journal:  Autoimmune Dis       Date:  2014-02-06
View more
  1 in total

1.  Different roles of urinary light chains and serum light chains as potential biomarkers for monitoring disease activity in systemic lupus erythematosus.

Authors:  Jun Jiang; Jin Zhao; Dan Liu; Man Zhang
Journal:  PeerJ       Date:  2022-05-17       Impact factor: 3.061

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.